Notice: This company has been marked as potentially delisted and may not be actively trading. Aquinox Pharmaceuticals (AQXP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends AQXP vs. TVTX, SYRE, PRAX, DAWN, OCUL, SNDX, RCUS, SPRY, AUPH, and MRVIShould you be buying Aquinox Pharmaceuticals stock or one of its competitors? The main competitors of Aquinox Pharmaceuticals include Travere Therapeutics (TVTX), Spyre Therapeutics (SYRE), Praxis Precision Medicines (PRAX), Day One Biopharmaceuticals (DAWN), Ocular Therapeutix (OCUL), Syndax Pharmaceuticals (SNDX), Arcus Biosciences (RCUS), ARS Pharmaceuticals (SPRY), Aurinia Pharmaceuticals (AUPH), and Maravai LifeSciences (MRVI). These companies are all part of the "medical" sector. Aquinox Pharmaceuticals vs. Travere Therapeutics Spyre Therapeutics Praxis Precision Medicines Day One Biopharmaceuticals Ocular Therapeutix Syndax Pharmaceuticals Arcus Biosciences ARS Pharmaceuticals Aurinia Pharmaceuticals Maravai LifeSciences Aquinox Pharmaceuticals (NASDAQ:AQXP) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings. Is AQXP or TVTX more profitable? Aquinox Pharmaceuticals has a net margin of 0.00% compared to Travere Therapeutics' net margin of -172.75%. Aquinox Pharmaceuticals' return on equity of -30.13% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aquinox PharmaceuticalsN/A -30.13% -28.08% Travere Therapeutics -172.75%-537.74%-55.65% Which has more risk and volatility, AQXP or TVTX? Aquinox Pharmaceuticals has a beta of -7.37, suggesting that its share price is 837% less volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500. Do institutionals & insiders have more ownership in AQXP or TVTX? 71.7% of Aquinox Pharmaceuticals shares are owned by institutional investors. 4.0% of Aquinox Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Travere Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to AQXP or TVTX? In the previous week, Travere Therapeutics had 4 more articles in the media than Aquinox Pharmaceuticals. MarketBeat recorded 4 mentions for Travere Therapeutics and 0 mentions for Aquinox Pharmaceuticals. Travere Therapeutics' average media sentiment score of 0.93 beat Aquinox Pharmaceuticals' score of 0.00 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Aquinox Pharmaceuticals Neutral Travere Therapeutics Positive Do analysts prefer AQXP or TVTX? Travere Therapeutics has a consensus target price of $22.62, suggesting a potential upside of 22.82%. Given Travere Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Travere Therapeutics is more favorable than Aquinox Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aquinox Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85 Which has higher earnings and valuation, AQXP or TVTX? Aquinox Pharmaceuticals has higher earnings, but lower revenue than Travere Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAquinox Pharmaceuticals$25M14.68-$31.58MN/AN/ATravere Therapeutics$145.24M9.90-$111.40M-$4.55-4.05 Does the MarketBeat Community prefer AQXP or TVTX? Aquinox Pharmaceuticals received 222 more outperform votes than Travere Therapeutics when rated by MarketBeat users. Likewise, 71.88% of users gave Aquinox Pharmaceuticals an outperform vote while only 57.04% of users gave Travere Therapeutics an outperform vote. CompanyUnderperformOutperformAquinox PharmaceuticalsOutperform Votes29971.88% Underperform Votes11728.13% Travere TherapeuticsOutperform Votes7757.04% Underperform Votes5842.96% SummaryAquinox Pharmaceuticals beats Travere Therapeutics on 9 of the 16 factors compared between the two stocks. Ad DTIDownload Our Tesla Ebook For FreeLike many of you, we here at the TradingPub are bullish on Tesla long term. We believe the company will continue to be a leader in technology, EVs and A.I. We also believe it’s share price will be rewarded in a big way… In fact, our #1 Tesla expert just published a brand new Ebook regarding Tesla’s future, and we’d like to send it to you at no cost.To claim your copy free of charge simply follow this link. Get Aquinox Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for AQXP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AQXP vs. The Competition Export to ExcelMetricAquinox PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$366.99M$6.51B$5.09B$8.84BDividend YieldN/A8.11%5.04%4.07%P/E RatioN/A6.16101.4814.96Price / Sales14.68366.491,207.9887.23Price / CashN/A52.5939.7136.27Price / Book5.0510.176.936.35Net Income-$31.58M$153.13M$118.81M$225.93M Aquinox Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AQXPAquinox PharmaceuticalsN/A$15.59+1.7%N/A+414.3%$366.99M$25M0.008TVTXTravere Therapeutics2.0329 of 5 stars$18.41+3.1%$22.62+22.8%+210.6%$1.44B$145.24M0.00460SYRESpyre Therapeutics2.3226 of 5 stars$27.00-1.8%$48.57+79.9%N/A$1.39B$890,000.00-3.61100News CoveragePRAXPraxis Precision Medicines1.778 of 5 stars$73.36-0.4%$146.33+99.5%+299.3%$1.37B$2.45M0.00110DAWNDay One Biopharmaceuticals1.9526 of 5 stars$13.34-2.1%$35.71+167.7%+12.4%$1.35BN/A0.0060Positive NewsOCULOcular Therapeutix3.7825 of 5 stars$8.52-3.0%$16.71+96.2%+273.6%$1.34B$58.44M-6.45267SNDXSyndax Pharmaceuticals4.025 of 5 stars$15.60-2.2%$37.64+141.3%+3.4%$1.33B$139.71M-4.16110Analyst ForecastAnalyst RevisionHigh Trading VolumeRCUSArcus Biosciences2.7633 of 5 stars$14.30-2.2%$34.00+137.8%+4.7%$1.31B$117M0.00500SPRYARS Pharmaceuticals2.7404 of 5 stars$13.42-1.0%$24.00+78.9%+183.5%$1.30B$30,000.000.0090Analyst RevisionAUPHAurinia Pharmaceuticals1.6688 of 5 stars$8.77+6.4%$10.00+14.0%-10.8%$1.26B$175.51M-54.93300MRVIMaravai LifeSciences4.7647 of 5 stars$4.96+2.9%$10.33+108.3%-2.2%$1.25B$288.95M0.00580 Related Companies and Tools Related Companies TVTX Competitors SYRE Competitors PRAX Competitors DAWN Competitors OCUL Competitors SNDX Competitors RCUS Competitors SPRY Competitors AUPH Competitors MRVI Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AQXP) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aquinox Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aquinox Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
